Biotech week ahead, July 30 2018

Biotech stocks saw modest gains this week, with earnings providing a boost even as clinical trial results elicited a mixed reaction.

Eli Lilly And Co (NYSE: LLY), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Gilead Sciences, Inc. (NASDAQ: GILD) are among some prominent biotechs that reported solid results and offered optimistic assessments for thenear-to-medium term.

Looking ahead to the upcoming week, biotech investors should watch for the following catalytic events.

Conferences

• Global Experts Meeting On Diabetes, Hypertension & Metabolic Syndrome: July 30-31 in Melbourne, Australia.
• 8th International Conference on Geriatrics Gerontology & Palliative Nursing: July 30-31 in Barcelona, Spain.
• International Pan Pacific Conference of ART & Perinatology: Aug. 3-5 in Las Vegas.

PDUFA Dates

FDA is set to announce its verdict on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)’s rare neuroendocrine tumor treatment candidate Azedra on Sunday, July 30.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and AbbVie Inc (NYSE: ABBV) await the FDA’s ruling on Elagolix for endometriosis-associated pain. Based on the three-month extension in the review period announced by the FDA on April 10, the decision could come in July or early August.

Earnings

Monday

• Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close)
• GenMark Diagnostics, Inc (NASDAQ: GNMK) (after the close)
• Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the open)

Tuesday

• Pulse Biosciences Inc (NASDAQ: PLSE) (after the close)
• Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the close)
• NewLink Genetics Corp (NASDAQ: NLNK) (after the close)
• Incyte Corporation (NASDAQ: INCY) (before the open)
• Medpace Holdings Inc (NASDAQ: MEDP) (before the open)
• Hologic, Inc. (NASDAQ: HOLX) (after the close)
• Pfizer Inc. (NYSE: PFE) (before the open)
• NuVasive, Inc. (NASDAQ: NUVA) (after the close)
• Qiagen NV (NYSE: QGEN)
• Illumina, Inc. (NASDAQ: ILMN) (after the close)

Wednesday

• Conatus Pharmaceuticals Inc (NASDAQ: CNAT) (after the close)
• Amarin Corporation plc (ADR) (NASDAQ: AMRN) (before the open)
• ArQule, Inc. (NASDAQ: ARQL) (before the open)
• AtriCure Inc. (NASDAQ: ATRC) (after the close)
• AxoGen, Inc (NASDAQ: AXGN)
• Blueprint Medicines Corp (NASDAQ: BPMC) (before the open)
• EXACT Sciences Corporation (NASDAQ: EXAS) (after the close)
• Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the close)
• Globus Medical Inc (NYSE: GMED) (after the close)
• IDEXX Laboratories, Inc. (NASDAQ: IDXX) (before the open)
• Clovis Oncology Inc (NASDAQ: CLVS) (after the close)
• DURECT Corporation (NASDAQ: DRRX) (after the close)
• Exelixis, Inc. (NASDAQ: EXEL) (after the close)

Thursday

• Genomic Health, Inc. (NASDAQ: GHDX) (after the close)
• Obalon Therapeutics Inc (NASDAQ: OBLN) (before the open)
• Acceleron Pharma Inc (NASDAQ: XLRN) (after the close)
• Insmed Incorporated (NASDAQ: INSM) (before the open)
• Seres Therapeutics Inc (NASDAQ: MCRB) (before the open)
• Curis, Inc. (NASDAQ: CRIS) (before the open)
• Acorda Therapeutics Inc (NASDAQ: ACOR) (before the open)
• AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) (after the close)
• Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the open)
• Becton Dickinson and Co (NYSE: BDX) (before the open)
• Arbutus Biopharma Corp (NASDAQ: ABUS) (after the close)
• Emergent Biosolutions Inc (NYSE: EBS) (after the close)
• T2 Biosystems Inc (NASDAQ: TTOO) (after the close)
• BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the close)
• Pacific Biosciences of California (NASDAQ: PACB) (after the close)
• Nevro Corp (NYSE: NVRO) (after the close)
• Cerus Corporation (NASDAQ: CERS) (after the close)
• TESARO Inc (NASDAQ: TSRO) (after the close)
• Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the open)
• Revance Therapeutics Inc (NASDAQ: RVNC) (after the close)
• Pacira Pharmaceuticals Inc (NASDAQ: PCRX) (before the open)
• Zoetis Inc (NYSE: ZTS) (before the open)
• ResMed Inc. (NYSE: RMD)
• Insulet Corporation (NASDAQ: PODD) (after the close)
• Glaukos Corp (NYSE: GKOS) (after the close)
• Repligen Corporation (NASDAQ: RGEN) (before the open)
• Epizyme Inc (NASDAQ: EPZM) (before the open)
• Aratana Therapeutics Inc (NASDAQ: PETX)

IPO

Bionano Genomics, an instrumentation company operating in the genome analysis space, is proposing to offer 3.35 million shares in an IPO, with the price range estimated between $8 and $10. The company intends to list its shares on the Nasdaq under the ticker symbol “BNGO.”

https://bit.ly/2LIrI4h